文献速递冠心病

超声心动图缺血记忆分子成像用于床旁检测心肌缺血

Echocardiographic Ischemic Memory Molecular Imaging for Point-of-Care Detection of Myocardial Ischemia.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

本研究在健康志愿者中确定磷脂酰丝氨酸微泡(MBPS)最佳剂量,并在30例冠脉造影后2小时内的稳定ACS患者中行床旁心肌造影超声(MCE)缺血记忆成像;结果显示缺血风险区分子成像信号强度显著高于远隔区域,区分两者C统计量为0.94,且信号与ACS类型、肌钙蛋白峰值、PCI时间等无关。

要点

  • 床旁MCE联合MBPS可在数分钟内检测近期已缓解的心肌缺血。
  • 缺血风险区信号显著高于远隔区,C统计量0.94。
  • 信号强度与ACS类型、肌钙蛋白峰值及PCI时间无关。

核心结论

  • 床旁超声心动图联合MBPS分子成像可检测近期已缓解的心肌缺血,且操作仅需数分钟。

研究设计与样本

  • 健康志愿者剂量探索研究(n=17)确定MBPS最佳剂量。
  • 稳定ACS患者(n=30)在冠脉造影及必要时PCI后2小时内行MCE分子成像。
  • 静脉给予MBPS后8分钟行MCE分子成像,并用MCE灌注成像评估缺血后微循环状态。

主要发现

  • ACS患者中除2例外均接受直接PCI。
  • 缺血后风险区MCE分子成像信号强度高于远隔区域(中位数[95%CI]:56[33-66] vs 8[2-17] IU;P<0.001)。
  • 区分缺血后与远隔区域的ROC曲线C统计量为0.94。
  • 风险区分子成像信号与ACS类型(不稳定型心绞痛3例、非ST段抬高型心肌梗死14例、ST段抬高型心肌梗死13例)、肌钙蛋白峰值、至PCI时间、PCI后心肌灌注、GRACE评分或HEART评分无关。

关键数值与推荐

  • 基于剂量探索研究,按体重选择MBPS剂量为0.10或0.15 mL。
  • MCE分子成像在静脉给予MBPS后8分钟进行。

临床怎么用

  • 床旁MCE联合MBPS分子成像可在ACS患者中快速检测近期已缓解的心肌缺血。
  • 该技术操作仅需数分钟,且信号强度似乎与缺血程度无关。

局限性

  • 研究纳入稳定ACS患者,需在冠脉造影及必要时PCI后2小时内完成成像。
  • 剂量探索仅在健康志愿者中进行,ACS患者样本量为30例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Noninvasive molecular imaging of recent ischemia can potentially be used to diagnose acute coronary syndrome (ACS) with high accuracy. OBJECTIVES: The authors hypothesized that bedside myocardial contrast echocardiography (MCE) ischemic memory imaging could be achieved with phosphatidylserine microbubbles (MBPS) that are retained in the microcirculation via ischemia-associated endothelial activation. METHODS: A dose-finding study was performed in healthy volunteers (n = 17) to establish optimal MBPS dosing. Stable patients with ACS (n = 30) and confirmed antecedent but resolved myocardial ischemia were studied within 2 hours of coronary angiography and percutaneous coronary intervention (PCI) when indicated. MCE molecular imaging was performed 8 minutes after intravenous administration of MBPS. MCE perfusion imaging was used to assess the status of the postischemic microcirculation. RESULTS: Based on dose-finding studies, 0.10 or 0.15 mL of MBPS based on body mass was selected. In patients with ACS, all but 2 underwent primary PCI. MCE molecular imaging signal intensity was greater in the postischemic risk area vs remote territory (median [95% CI]: 56 [33-66] vs 8 [2-17] IU; P < 0.001) with a receiver-operating characteristic curve C-statistic of 0.94 to differentiate post-ischemic from remote territory. Molecular imaging signal in the risk area was not related to type of ACS (unstable angina: 3; non-ST-segment elevation myocardial infarction: 14; ST-segment elevation myocardial infarction: 13), peak troponin, time to PCI, post-PCI myocardial perfusion, GRACE (Global Registry of Acute Coronary Events) score, or HEART score. CONCLUSIONS: Molecular imaging with point-of-care echocardiography and MBPS can detect recent but resolved myocardial ischemia. This bedside technique requires only minutes to perform and appears independent of the degree of ischemia. (Ischemic Memory Imaging With Myocardial Contrast Echocardiography; NCT03009266).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Davidson, Hodovan, Layoun, et al. Echocardiographic Ischemic Memory Molecular Imaging for Point-of-Care Detection of Myocardial Ischemia. J Am Coll Cardiol. 2021. PMID: 34763776. doi:10.1016/j.jacc.2021.08.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。